Author

Mandodari Rajurkar

Observed names: M. Rajurkar, Mandodari N. Rajurkar, Rajurkar Dr Mandodari

Institution: Sun Pharma (India)

Observed institution: Sun Pharma (India)

ORCID: 0000-0002-5513-0545

Observed ORCID: 0000-0002-5513-0545

OpenAlex ID: A5092052385

Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations

2023 · Rakesh K. Sahay, Richa Giri, et al. · Advances in Therapy · 30

Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study

2024 · Asim K. Ghosh, Usha S. Nikumbh, et al. · Ophthalmology and Therapy · 12

Fixed dose combination of dapagliflozin, glimepiride and extended‐release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III , open label, randomized clinical study in India

2025 · Rakesh Sahay, Dinesh Gangwani, et al. · Diabetes Obesity and Metabolism · 9

A fixed dose combination of tamsulosin and tadalafil in men with benign prostatic hyperplasia and erectile dysfunction: a prospective, multicenter, phase IV study

2026 · Chirag Gupta, Avinash T. S., et al. · World Journal of Urology · 1

Safety and Effectiveness of a Fixed-Dose Combination of Cephalexin Extended Release and Clavulanate Potassium in Bacterial Sore Throat and Uncomplicated Skin and Soft-Tissue Infections: A Multicentre, Open-Label, Phase IV Study in India

2026 · Sunil Panda, Shrinivas Chavan, et al. · Drugs - Real World Outcomes · 1

1150: Fexuprazan, a Novel Potassium-competitive Acid Blocker Vs. Esomeprazole in Indian Patients With Erosive Esophagitis: a Phase 3, Multicentre, Randomized, Active-controlled Study

2025 · Shravan Kumar, Santosh Hajare, et al. · Gastroenterology · 1

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients with HbA1c 9%-11%

2024 · Prakash Kurmi, Manish Singh, et al. · Endocrine Abstracts · 1

A Prospective, Multicenter, Single-arm, Phase IV Study to Assess the Safety and Effectiveness of a Fixed-Dose Combination of Pregabalin Prolonged Release and Etoricoxib in Patients with Chronic Low Back Pain with a Neuropathic Component

2026 · Sandesh Sahebrao Patil, Brijesh Jerambhai Patel, et al. · Drugs - Real World Outcomes

Author response for "Fixed dose combination of dapagliflozin, glimepiride and extended‐release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III , open label, randomized clinical study in India"

2025 · Rakesh Sahay, Dinesh Gangwani, et al. · Publons reviews and discussion

Author response for "Fixed dose combination of dapagliflozin, glimepiride and extended‐release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III , open label, randomized clinical study in India"

2024 · Rakesh Sahay, Dinesh Gangwani, et al. · Publons reviews and discussion

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients aged <45 years and 45 to 65 years

2024 · Prakash Kurmi, Manish Singh, et al. · Endocrine Abstracts

Efficacy and safety of fixed dose combination of silodosin and tadalafil in Indian patients with benign prostatic hyperplasia and erectile dysfunction: A phase 3 randomized clinical study

2024 · T.S. Avinash, P. Mondal, et al. · European Urology

IDF23-0498 Subgroup analysis of Phase 3 study of dapagliflozin, glimepiride and metformin ER FDC in T2DM patients with HbA1c 9%–11%

2024 · R. Sahay, D. Gangwani, et al. · Diabetes Research and Clinical Practice

Gender-specific treatment response to pimavanserin in Parkinson’s disease psychosis: a post-hoc analysis of phase-3 study in Indian population

2024 · B. Kathiriya, Y. Patidar, et al. · Neuroscience Applied

S512 Effect of Esomeprazole Dual Release Gastro-Resistant Tablets in Patients With Refractory Gastroesophageal Reflux Disease in Comparison to Esomeprazole Tablets: A Double-Blind Randomized, Phase 3 Active-Controlled Trial

2023 · Vinay Kumar, Pankaj Nemade, et al. · The American Journal of Gastroenterology

Works count: 15

Citation count: 55

H-index: 3

I10-index: 2